Ann: Immutep Investor Update, page-14

Furthermore, Marc's closing paragraph....

As we begin 2022, I believe we are entering an exciting period of breakthrough clinical developments that
will validate the LAG-3 opportunity the Immutep team has been sharing with investors for years. The
turning point for this moment of clarity will be across the LAG-3 therapeutic space, as the FDA is expected
to approve the first LAG-3 based therapy and numerous late-stage studies are slated to begin, including
our program. Furthermore, the first ever LAG-3 summit in January was a great success.

fda expected to give BMS the nod in mid/late march, I presume Marc is better informed in this regard than
we would be, but anyhow, If this indeed happens I will be watching the markets reaction which will be reflected
in BMS share price, and more importantly if considerable, will it flow on to immutep?

IMO there may be a tardy sustainable reaction until the market can absorb the relevance of lag-3 discovery and the
news filters through to the broader market rather than simply the biotech sector....